Cargando…
Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study
Background: The purpose of this trial was to evaluate the effectiveness and safety of the IL-6 receptor antibody Tocilizumab (TCZ) in the treatment of Familial Mediterranean Fever (FMF). Methods: This was a randomized, double-blinded, placebo-controlled phase II trial in adult patients with active F...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500594/ https://www.ncbi.nlm.nih.gov/pubmed/36143006 http://dx.doi.org/10.3390/jcm11185360 |
_version_ | 1784795258476822528 |
---|---|
author | Henes, Joerg C. Saur, Sebastian Kofler, David M. Kedor, Claudia Meisner, Christoph Schuett, Marion Krusche, Martin Koetter, Ina Xenitidis, Theodoros Schulze-Koops, Hendrik Feist, Eugen |
author_facet | Henes, Joerg C. Saur, Sebastian Kofler, David M. Kedor, Claudia Meisner, Christoph Schuett, Marion Krusche, Martin Koetter, Ina Xenitidis, Theodoros Schulze-Koops, Hendrik Feist, Eugen |
author_sort | Henes, Joerg C. |
collection | PubMed |
description | Background: The purpose of this trial was to evaluate the effectiveness and safety of the IL-6 receptor antibody Tocilizumab (TCZ) in the treatment of Familial Mediterranean Fever (FMF). Methods: This was a randomized, double-blinded, placebo-controlled phase II trial in adult patients with active FMF and an inadequate response or intolerance to colchicine (crFMF). The physician’s global assessment of disease activity (PGA), based on a five-point scale for six symptoms, was used as a clinical score, which had to be >2 at screening, together with elevated c-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) levels, to be eligible for inclusion. Patients were randomized 1:1 to either receive monthly TCZ or a placebo over a period of 24 weeks. The primary endpoint was the number of patients achieving an adequate response to treatment at week 16, defined as a PGA of ≤2 and normalized ESR or CRP and normalized SAA. Results: We randomized 25 patients with a median age of 31 years. At week 16, an adequate treatment response was achieved by two patients in the TCZ and none of the patients in the placebo arm (p = 0.089). SAA levels normalized with TCZ, but not with the placebo (p = 0.015). Conclusion: In this first randomized, placebo-controlled study in patients with active crFMF, more patients in the TCZ arm experienced a response to treatment in comparison to those receiving the placebo. As the prevention of amyloidosis is a major treatment goal in FMF, the normalization of SAA in TCZ-treated patients is essential. These findings have to be confirmed in a larger trial. |
format | Online Article Text |
id | pubmed-9500594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95005942022-09-24 Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study Henes, Joerg C. Saur, Sebastian Kofler, David M. Kedor, Claudia Meisner, Christoph Schuett, Marion Krusche, Martin Koetter, Ina Xenitidis, Theodoros Schulze-Koops, Hendrik Feist, Eugen J Clin Med Article Background: The purpose of this trial was to evaluate the effectiveness and safety of the IL-6 receptor antibody Tocilizumab (TCZ) in the treatment of Familial Mediterranean Fever (FMF). Methods: This was a randomized, double-blinded, placebo-controlled phase II trial in adult patients with active FMF and an inadequate response or intolerance to colchicine (crFMF). The physician’s global assessment of disease activity (PGA), based on a five-point scale for six symptoms, was used as a clinical score, which had to be >2 at screening, together with elevated c-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) levels, to be eligible for inclusion. Patients were randomized 1:1 to either receive monthly TCZ or a placebo over a period of 24 weeks. The primary endpoint was the number of patients achieving an adequate response to treatment at week 16, defined as a PGA of ≤2 and normalized ESR or CRP and normalized SAA. Results: We randomized 25 patients with a median age of 31 years. At week 16, an adequate treatment response was achieved by two patients in the TCZ and none of the patients in the placebo arm (p = 0.089). SAA levels normalized with TCZ, but not with the placebo (p = 0.015). Conclusion: In this first randomized, placebo-controlled study in patients with active crFMF, more patients in the TCZ arm experienced a response to treatment in comparison to those receiving the placebo. As the prevention of amyloidosis is a major treatment goal in FMF, the normalization of SAA in TCZ-treated patients is essential. These findings have to be confirmed in a larger trial. MDPI 2022-09-13 /pmc/articles/PMC9500594/ /pubmed/36143006 http://dx.doi.org/10.3390/jcm11185360 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Henes, Joerg C. Saur, Sebastian Kofler, David M. Kedor, Claudia Meisner, Christoph Schuett, Marion Krusche, Martin Koetter, Ina Xenitidis, Theodoros Schulze-Koops, Hendrik Feist, Eugen Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study |
title | Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study |
title_full | Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study |
title_fullStr | Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study |
title_full_unstemmed | Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study |
title_short | Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study |
title_sort | tocilizumab for the treatment of familial mediterranean fever—a randomized, double-blind, placebo-controlled phase ii study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500594/ https://www.ncbi.nlm.nih.gov/pubmed/36143006 http://dx.doi.org/10.3390/jcm11185360 |
work_keys_str_mv | AT henesjoergc tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT saursebastian tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT koflerdavidm tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT kedorclaudia tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT meisnerchristoph tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT schuettmarion tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT kruschemartin tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT koetterina tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT xenitidistheodoros tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT schulzekoopshendrik tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy AT feisteugen tocilizumabforthetreatmentoffamilialmediterraneanfeverarandomizeddoubleblindplacebocontrolledphaseiistudy |